NV-YUPPTV
One of the world’s largest internet-based TV and On-demand service provider for South Asian content, YuppTV, announced the launch of Freedocast Pro Device and Freedocast Live Streaming Platform. Providing end-to-end solutions for users to go LIVE instantly, anywhere anytime, the Pro Device & Live-Streaming platform also enables users to broadcast live videos on multiple platforms such as, Facebook and YouTube Live, Twitter/Periscope and others.
The latest offering, Freedocast Pro Device broadcasts live videos in HD Quality . The Device can be connected to any video source including camera and switcher to go live and can be easily controlled via Android/iOS App. The App can be used to preview, control & monitor live broadcasts. The Device also has a rechargeable battery supporting over 2 hours of continuous live streaming and offers HDMI IN/OUT & MIC-in for AV source connectivity.
To best suit the needs of broadcasters, Freedocast Live Streaming Platform is designed as a one-stop-solution providing cloud transcoding & Adaptive Bitrate streaming for best viewing experience in low bandwidths, real-time analytics, viewer interactivity with chat moderation, Ad-integration, pay-per-view, geo-blocking & password protection for control of events. Any external encoder can be used to go live through Freedocast Platform and simultaneously stream to multiple platforms.
Commenting on the launch, Uday Reddy, Founder and CEO of YuppTV said, “The rapid growth of Live broadcasting could change the way users consume content. In this age of information overload, people expect to see events unfold in real-time. Globally renowned for our technical superiority in the field of internet TV and OTT, we at YuppTV are now extending the same expertise in live-streaming. With the launch of Freedocast Pro Device & Freedocast Live Streaming Platform, we further intend to deliver cost-effective, scalable, and robust LIVE broadcasting solutions. We shall continue to innovate and provide the best services to constantly address the needs of our users.”
Freedocast offers tailor-made solutions for broadcasters to aggregate, edit and broadcast events in-real time to their studios and multiple platforms. This solution is aimed to improve Broadcasters efficiency and productivity to stay ahead of competition. Celebrities and influencers can maximize the value of their social media programs by hosting special interactive sessions through Freedocast. Broadcasting sporting events, webinars, etc. can be streamed to multiple platforms to increase the audience size and bring in new revenue streams for the broadcasters.
YuppTV will demonstrate its new offering Freedocast Pro and Freedocast Platform at NAB show 2017 at YuppTV booth SU11402CM, Las Vegas Convention Centre.
About Freedocast
Freedocast is a product by YuppTV, pioneer and one of the world’s largest online over-the-top (OTT) entertainment solutions provider. Freedocast is a live broadcasting solution which enables the user to live stream instantly anywhere anytime. Broadcast simultaneously to multiple platforms like fb Live, YouTube Live, etc. Freedocast provides Adaptive Bitrate Streaming which enables streaming even in low bandwidth.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170424005869/en/
Contact:
YuppTV
Pooja Diwan, +91 40 23555055
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 00:45:00 CEST | Press release
POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free survival and overall survival In May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz® (retifanlimab-dlwr) in combination with carboplatin and paclitaxel and as a single agent for the treatment of advanced SCAC; submissions to other global regulatory agencies are also under review Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-base
Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 21:30:00 CEST | Press release
Progress in natural refrigerants, water efficiency and circular economy underscores Güntner’s global impact Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal,
Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 20:45:00 CEST | Press release
Windsurf launches a GPU cluster in Germany, delivering 50% faster performance and secure access to European enterprises. Data residency ensures enterprise repositories stay within the EU, meeting stringent security requirements. Windsurf already supports 100+ European enterprise customers, highlighting strong demand for AI-powered development tools across EMEA. Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of
Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 19:00:00 CEST | Press release
New SDK Integration Simplifies Monetization for Defold Developers Publishing on CrazyGames Ahead of Global Game Jam Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization jou
Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 17:00:00 CEST | Press release
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom